Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test

Pharmacological Reports

Volumn 60, Issue 6, 2008, Pages 880-888

  Rogóz, Zofia ^a   Skuza, Grazyna ^a   Leśkiewicz, Monika ^a   Budziszewska, Bogusłlawa ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Corticosterone; Fluoxetine; Forced swim test; Metyrapone; Rats; Tianeptine

Indexed keywords

CORTICOSTERONE; FLUOXETINE; METYRAPONE; PRAZOSIN; SEROTONIN 1A ANTAGONIST; TIANEPTINE; ANTIDEPRESSANT AGENT; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; SEROTONIN 1A RECEPTOR; THIAZEPINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; DRUG ACTIVITY; DRUG POTENTIATION; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MONOTHERAPY; NONHUMAN; OPEN FIELD TEST; RAT; ANIMAL; BLOOD; DEPRESSION; DRUG COMBINATION; DRUG EFFECT; EXPLORATORY BEHAVIOR; PHYSIOLOGY; SWIMMING; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; DEPRESSION; DRUG THERAPY, COMBINATION; EXPLORATORY BEHAVIOR; FLUOXETINE; MALE; METYRAPONE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; SWIMMING; THIAZEPINES;

EID: 65249159686     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Baez M, Volosin M: Corticosterone influences forced swim-induced immobility. Pharmacol Biochem Behav, 1994, 49, 729-736.
2. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M: Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. J Clin Invest, 1991, 87, 831-837.
3. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord, 2001, 64, 261-265.
4. 1A receptor mRNA expression. Trends Neurosci, 1993, 13, 914-923.
5. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE: Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav, 2000, 65, 591-597.
6. Connor TJ, Kelly JP, Leonard BE: Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol Biochem Behav, 1998, 59, 171-177.
7. Cryan JF, Page ME, Lucki I: Differential behavioral effect of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl), 2005, 182, 335-344.
8. Detke MJ, Lucki I: Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test. The effects of water depth. Behav Brain Res, 1995, 73, 43-46.
9. Detke MJ, Rickels M Lucki I: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl), 1995, 121, 66-72.
10. Dimitriou EC, Dimitriou CE: Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol, 1998, 18, 465-469.
11. Duncan GE, Knapp DJ, Carson SW, Breese GR: Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther, 1998, 285, 579-589.
12. 1A receptor antagonist, WAY 100635. Eur J Pharmacol, 1995, 281, 81-88.
13. 1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berl), 1987, 91, 500-505.
14. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE: Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl), 1999, 145, 203-208.
15. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry, 1996, 153, 93-99.
16. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
17. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenalcortical regulation. Endocrine Rev, 1996, 17, 187-205.
18. Holsboer F, Gerken A, Stalla GK, Muller O: ACTH, cortisol and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry, 1985, 20, 276-286.
19. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridias A, Wiedemann K: Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry, 2004, 61, 1235-1244.
20. Janssen PAJ, Jageneau AHM, Schellekens KHL: Chemistry and pharmacology of compounds releated to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. Part IV. Influence of haloperidol (R 1625) or chloropromazine on the behaviour of rats in unfamiliar "open field" situation. Psychopharmacologia, 1960, 1, 389-392.
21. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med, 1979, 48, 465-472.
22. Karandrea D, Kittas C, Kitraki E: Forced swimming differential affects male and female brain corticosteroid receptors. Neuroendocrinology, 2002, 75, 217-226.
23. Kennett GA, Dickinson SL, Curzon G: Central serotonergic responses and behavioral adaptation to repeated immobilization: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol, 1985, 119, 143-152.
24. Korstein SG, Schneider RK: Clinical festures of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
25. Kuroda Y, Watanable Y, McEwen BS: Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain. Eur J Pharmacol, 1994, 268, R3-R5.
26. Lesch KP, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL: Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol Brain Res, 1993, 17, 31-35.
27. Linkowski P, Mendlewicz J, LeClerc R, Brasseur M, Hubain P, Goldstein J, Copinschi G, Van Cauter E: The 24-hour profile of ACTH and cortisol in major depressive illness. J Clin Endocrinol Metab, 1985, 61, 429-438.
28. Maes M, Vandoolaeghe E, Desnyder R: Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord, 1996, 41, 201-210.
29. A receptor. Mechanism of action and physiological significance. Prog Neurobiol, 1992, 38, 379-395.
30. Molodavkin GM, Voronina TA, Meletova OK: Comparative study of the antidepressant and anxiolytic activity of fluoxetine and tianeptine (Russian). Eksp Klin Farmakol, 2005, 68, 10-12.
31. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoendocrinology, 1997, 22, Suppl 1, S125-S132.
32. Nemeroff CB, Widerlov E, Bisette G, Walleus H, Karlsson I, Eklund K, Kilts CD et al.: Elevated concentrations of CRF corticotropin releasing factor-like immunoreactivity in depressed patients. Science, 1984, 226, 1342-1344.
33. Nowakowska E, Kuś K, Chodera A, Rybakowski J: Behavioral effects of fluoxetine and tianeptine, two antidepressants with opposite action mechanisms, in rats. Arzneimittelforschung, 2000, 50, 5-10.
34. O'Brien D, Skelton KH, Owens MJ, Nemeroff CB: Are CRF receptor antagonists potential antidepressants? Hum Psychopharmacol, 2001, 16, 81-87.
35. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry, 2001, 49, 391-404.
36. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioral despair in rats, a new model sensitive to antidepressant treatment. Eur J Pharmacol, 1978, 47, 379-391.
37. Price LH, Malison RT, McDougle CJ, Pelton GH: Anti-glucocorticoids as treatments for depression. Rationale for use and therapeutic potential. CNS Drugs, 1996, 5, 311-320.
38. Raven PW, O'Dwyer A-M, Taylor NF, Checkley SA: The relationship between the effect of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology, 1996, 21, 277-286.
39. 1-adrenergic system in rats. Pharmacol Rep, 2007, 59, 588-594.
40. Rogóz Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W: Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol, 2005, 56, 49-61.
41. Rogóz Z, Skuza G: Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep, 2006, 58, 493-500.
42. Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A: Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep, 2007, 59, 778-784.
43. Rogóz Z, Skuza G, Wójcikowski J, Daniel WA: Effect of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol, 2003, 55, 993-999.
44. Rogóz Z, Skuza G, Wójcikowski J, Daniel WA, Wróbel A, Dudek D, Zieba A: Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol, 2004, 56, 849-855.
45. Roozendaal B, Bohus B, McGaugh JL: Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory. Psychoendocrinology, 1996, 21, 681-693.
46. Satoh T, Yamada K, Tsuboi M: Effect of imipramine on serum corticosterone levels in forced swimming rats. Res Commun Psychol Psychiatr Behav, 1985, 10, 235-238.
47. 2 receptors and transport sites for serotonin. Brain Res, 1993, 615, 87-94.